Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram

Tamoxifen remains an important adjuvant therapy to reduce the rate of breast cancer recurrence among patients with oestrogen-receptor-positive tumours. Cytochrome P-450 2D6 metabolises tamoxifen to metabolites that more readily bind the oestrogen receptor. This enzyme also metabolises selective sero...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Lash, T L, Pedersen, L, Cronin-Fenton, D, Ahern, T P, Rosenberg, C L, Lunetta, K L, Silliman, R A, Hamilton-Dutoit, S, Garne, J P, Ewertz, M, Sørensen, H T
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group 2008
Fag:
Clinical Study
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2527838/
https://ncbi.nlm.nih.gov/pubmed/18665165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604533
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker